The efficacy of everolimus in combination with exemestane has been tested in a phase III clinical study (BOLERO-2), in 724 patients with HR+ advanced breast cancer after non-steroidal aromatase inhibitor therapy, where it was associated with a markedly improved median PFS (7.8 months) versus a placebo plus exemestane (3.2 months). Here, CYP19A1 is linked to breast carcinoma.